Michael Lahn

Company: iOnctura SA

Job title: Chief Medical Officer


Leveraging the Lessons from Past Drug Development Experiences 2:10 pm

Exploring the degree of inhibition to achieve clinically meaningful outcomes Using preclinical data to predict target modulation and efficacy in patients Navigating alternative pathways to target TGF-β signalling, including blocking the enzyme autotaxinRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.